Shilpa Medicare (SHILPAMED.BO) Earnings Analysis
Shilpa Medicare (SHILPAMED.BO) next reports earnings on 2026-08-06, consensus EPS 4 INR. Last quarter (2026-05-22) it beat with EPS 5.5 INR vs 3.3 INR est (+66.7%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 48.48.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SHILPAMED.BO next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 4 INR |
| Revenue estimate | 4.60B |
SHILPAMED.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-22 | 5.5 INR | 3.3 INR | +66.7% | Beat |
| 2026-02-06 | 2.3 INR | 2.8 INR | -17.9% | Miss |
| 2025-11-13 | 2.25 INR | 4.4 INR | -48.9% | Miss |
| 2025-08-13 | 2.4 INR | 1.85 INR | +29.7% | Beat |
| 2025-05-26 | 1.7 INR | 2.95 INR | -42.4% | Miss |
| 2025-02-10 | 3.25 INR | n/a | n/a | n/a |
Beat rate: 2/5 (40%) over reported quarters with consensus data.
SHILPAMED.BO valuation and analyst view
| Trailing P/E | 48.48 |
|---|---|
| Trailing EPS | 12.438 INR |
| Price / book | 4.55 |
| Dividend yield | 0.08% |
| Market cap | 59.99B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Shilpa Medicare (SHILPAMED.BO)'s next earnings date?
Shilpa Medicare is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 4 INR and revenue estimate of 4.60B.
Did SHILPAMED.BO beat earnings last quarter?
In its 2026-05-22 report, SHILPAMED.BO posted EPS of 5.5 INR versus a 3.3 INR estimate — a beat of 66.7%.
What is SHILPAMED.BO's earnings track record?
Over the last 5 reported quarters with consensus data, SHILPAMED.BO beat estimates 2 times (40%).
What is SHILPAMED.BO's current P/E ratio and EPS?
SHILPAMED.BO trades at a trailing P/E of 48.48 on trailing EPS of 12.438249516935377 INR.
What do analysts rate SHILPAMED.BO?
SHILPAMED.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.